JP7456662B2 - 中性脂肪蓄積型動脈硬化退縮剤 - Google Patents
中性脂肪蓄積型動脈硬化退縮剤 Download PDFInfo
- Publication number
- JP7456662B2 JP7456662B2 JP2022514027A JP2022514027A JP7456662B2 JP 7456662 B2 JP7456662 B2 JP 7456662B2 JP 2022514027 A JP2022514027 A JP 2022514027A JP 2022514027 A JP2022514027 A JP 2022514027A JP 7456662 B2 JP7456662 B2 JP 7456662B2
- Authority
- JP
- Japan
- Prior art keywords
- arteriosclerosis
- neutral fat
- fat accumulation
- tricaprin
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022127299A JP2022166145A (ja) | 2020-05-22 | 2022-08-09 | 中性脂肪蓄積型動脈硬化退縮剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020090091 | 2020-05-22 | ||
| JP2020090091 | 2020-05-22 | ||
| JP2020192099 | 2020-11-18 | ||
| JP2020192099 | 2020-11-18 | ||
| PCT/JP2021/008689 WO2021235044A1 (ja) | 2020-05-22 | 2021-03-05 | 中性脂肪蓄積型動脈硬化退縮剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127299A Division JP2022166145A (ja) | 2020-05-22 | 2022-08-09 | 中性脂肪蓄積型動脈硬化退縮剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021235044A1 JPWO2021235044A1 (cg-RX-API-DMAC7.html) | 2021-11-25 |
| JPWO2021235044A5 JPWO2021235044A5 (cg-RX-API-DMAC7.html) | 2022-05-12 |
| JP7456662B2 true JP7456662B2 (ja) | 2024-03-27 |
Family
ID=78708421
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514027A Active JP7456662B2 (ja) | 2020-05-22 | 2021-03-05 | 中性脂肪蓄積型動脈硬化退縮剤 |
| JP2022127299A Pending JP2022166145A (ja) | 2020-05-22 | 2022-08-09 | 中性脂肪蓄積型動脈硬化退縮剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127299A Pending JP2022166145A (ja) | 2020-05-22 | 2022-08-09 | 中性脂肪蓄積型動脈硬化退縮剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12576061B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4154877A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7456662B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021235044A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7236119B2 (ja) * | 2019-06-21 | 2023-03-09 | 学校法人近畿大学 | 大動脈瘤の予防用医薬組成物および加工食品 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013031729A1 (ja) | 2011-08-26 | 2013-03-07 | 国立大学法人大阪大学 | 糖尿病性心血管合併症の予防・治療剤 |
-
2021
- 2021-03-05 WO PCT/JP2021/008689 patent/WO2021235044A1/ja not_active Ceased
- 2021-03-05 US US17/926,301 patent/US12576061B2/en active Active
- 2021-03-05 JP JP2022514027A patent/JP7456662B2/ja active Active
- 2021-03-05 EP EP21809755.8A patent/EP4154877A4/en active Pending
-
2022
- 2022-08-09 JP JP2022127299A patent/JP2022166145A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013031729A1 (ja) | 2011-08-26 | 2013-03-07 | 国立大学法人大阪大学 | 糖尿病性心血管合併症の予防・治療剤 |
Non-Patent Citations (6)
| Title |
|---|
| J. Oleo Sci. 67(8) (2018),983-989 |
| Orphan. J. Rare Dis. 14 (2019),134 |
| 中性脂肪蓄積心筋血管症に対する中鎖脂肪酸を含有する医薬品の開発,2014年,[https://mhlw-grants.niph.go.jp/project/21812] |
| 中性脂肪蓄積心筋血管症に対する中鎖脂肪酸を含有する医薬品の開発,平成24年度総括・分担研究報告書,2014年,[https://mhlw-grants.niph.go.jp/system/files/2012/123151/201231167A/201231167A0001.pdf] |
| 新たな開催日決定:中性脂肪蓄積心筋血管症(TGCV)研究10年の歩みと今後の展望,大阪大学大学院医学系研究科・医学部,2019年,[https://web.archive.org/web/20191109093741/https://www.med.osaka-u.ac.jp/education/society/seminar/article20181113-2] |
| 日循協誌,1996年,第30巻第3号,pp.236-242 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2021235044A1 (cg-RX-API-DMAC7.html) | 2021-11-25 |
| WO2021235044A1 (ja) | 2021-11-25 |
| EP4154877A4 (en) | 2024-05-29 |
| US12576061B2 (en) | 2026-03-17 |
| JP2022166145A (ja) | 2022-11-01 |
| EP4154877A1 (en) | 2023-03-29 |
| US20230210805A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stirban et al. | Effects of n–3 fatty acids on macro-and microvascular function in subjects with type 2 diabetes mellitus | |
| Yonemura et al. | Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging | |
| Wu et al. | Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial | |
| Nettleton et al. | n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review | |
| Angerer et al. | Effect of dietary supplementation with ω-3 fatty acids on progression of atherosclerosis in carotid arteries | |
| Amano et al. | Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study | |
| Giannini et al. | Influence of the Mediterranean diet on carotid intima–media thickness in hypercholesterolaemic children: a 12-month intervention study | |
| JPWO2004112777A1 (ja) | 下肢静脈瘤予防・治療用組成物 | |
| JPWO2012063820A1 (ja) | 血糖値上昇抑制剤 | |
| JP5810166B2 (ja) | 糖尿病性心血管合併症の予防・治療剤 | |
| Lee et al. | Effect of altering dietary n-6: n-3 PUFA ratio on cardiovascular risk measures in patients treated with statins: a pilot study | |
| Bemelmans et al. | Change in saturated fat intake is associated with progression of carotid and femoral intima-media thickness, and with levels of soluble intercellular adhesion molecule-1 | |
| Nowak et al. | Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants | |
| Vermeer et al. | Effect of Menaquinone-7 (vitamin K2) on vascular elasticity in healthy subjects: results from a one-year study | |
| JP2022166145A (ja) | 中性脂肪蓄積型動脈硬化退縮剤 | |
| JP2009051732A (ja) | Pparリガンド活性を有する組成物 | |
| Briand et al. | Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD | |
| WO2004022049A1 (ja) | 痩身剤およびその飲食物 | |
| Haberka et al. | Obesity, ultrasound indexes of fat depots and lipid goal attainment in patients with high and very high cardiovascular risk: A novel approach towards better risk reduction | |
| WO2012108379A1 (ja) | 拡張性うっ血性心不全治療剤 | |
| Zhang et al. | Cardiac and arterial calcifications and all-cause mortality in the elderly: the PROTEGER Study | |
| CN101426492A (zh) | 饮食后血中胰岛素上升抑制剂 | |
| Ciccone et al. | Endothelial function in obese and overweight patients: the role of olive oil, fish and nuts | |
| Aljuraiban et al. | 182 association of number of daily eating episodes with blood pressure and nutrient intake: intermap study | |
| WO2004022051A1 (ja) | ペルオキシソーム増殖薬活性化受容体調整剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220301 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220301 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220301 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220329 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220510 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240129 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240307 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7456662 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |